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Changes in Serum Creatinine Concentration and Acute Kidney Injury
(AKI) Grade in Dogs Treated with Hydroxyethyl Starch 130/0.4
From 2013 to 2015
N.E. Sigrist, N. K€alin, and A. Dreyfus
Background: Hydroxyethyl starch (HES) solutions may cause acute kidney injury (AKI) in humans.
Objective: To compare AKI grades in 94 dogs exposed and 90 dogs that were unexposed to 6% HES-130/0.4.
Animals: Dogs receiving 6% HES-130/0.4 (HES cohort) or crystalloids (unexposed cohort) between 2013 and 2015.
Methods: Historical cohort study. Diagnosis, total cumulative dose and total mL/kg of HES administered, time frame of
HES administration and serum creatinine concentrations up to 90 days after initiation of HES treatment were retrospectively
reviewed. The AKI grades were retrospectively determined by IRIS guidelines.
Results: Exposed dogs received a median cumulative dose of 69.4 mL/kg (range, 2–429 mL/kg) HES over a median of 4
(range, 1–16) days, resulting in a median dose of 20.7 (range, 2–87) mL/kg/d. Although the cohorts diﬀered in terms of age
and diagnosis, AKI grades were not signiﬁcantly diﬀerent at the evaluated short- and long-term time points. Results of ordi-
nal logistic regression identiﬁed the number of days of HES administration as signiﬁcantly associated with an increase in
AKI grade within 10 days (P = .038), whereas there was no signiﬁcant association among HES exposure, HES mL/kg/d, and
an increase in AKI grade.
Conclusions and Clinical Importance: HES-130/0.4-treated dogs were not more prone to develop AKI than HES-
untreated, but the number of HES days was signiﬁcantly associated with an increase in AKI grade within 10 days post-HES
administration. The time frame of HES treatment should be kept short. Prospective, randomized clinical trials are required
to assess the eﬀect of HES on renal function in dogs.
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Hydroxyethyl starch (HES) is an artiﬁcial colloidsolution widely used for resuscitation in veterinary
patients. Hydroxyethyl starch increases colloid osmotic
pressure,1,2 systolic blood pressure2,3,a , and blood
volume.3,4 Indications for colloid use therefore include
hypovolemia, hypotension, perioperative ﬂuid therapy,
low colloid osmotic pressure, or hypoalbuminemia.5,6
Recently, the safety of HES in dogs has been ques-
tioned because several large trials in human patients
have shown that HES administration increased the need
for renal replacement therapy7–9 or increased mortality9,
speciﬁcally in patients with sepsis.7,9,10 Based on avail-
able data, the Pharmacovigilance Risk Assessment
Committee (PRAC) of the European Medicine Agency
(EMA) subsequently limited the indications for HES
treatment in human patients. Since October 2013, the
administration of HES solutions has been restricted to
hypovolemic shock in trauma patients and is con-
traindicated in septic and critically ill human patients as
well as burn victims in the European Union (PRAC
statementb ).
In veterinary medicine, the adverse eﬀects of HES
administration on platelet function and coagulation are
well documented in dogs.11–13 Studies investigating
potential adverse renal eﬀects of HES solutions, how-
ever, are rare in dogs. Conﬂicting results were found
regarding the incidence of acute kidney injury (AKI)
after HES administration in hospitalized dogs receiving
HES solutions.14,15 The incidence of AKI, deﬁned as a
doubling of serum creatinine concentration during hos-
pitalization, was increased in dogs receiving a pen-
tastarch solution (10% HES-250/0.5/5:1).14 In Europe,
pentastarches mostly have been replaced by tetra-
starches. The only study evaluating dogs receiving 6%
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HES-130/0.4 found no signiﬁcant increase in serum cre-
atinine concentrations.15 Studies investigating adverse
renal eﬀects, and speciﬁcally the incidence of AKI after
HES administration, in veterinary patients therefore are
needed.
Considering the lack of alternative options, HES
solutions remain an important choice of ﬂuid therapy in
selected cases. The goal of our historical cohort study
was to determine whether administration of the cur-
rently available 6% HES-130/0.4 is associated with an
increase in serum creatinine concentration and AKI
grade as deﬁned by International Renal Interest Society
(IRIS) guidelinesc (Table 1) in dogs. We distinguished
between an immediate HES eﬀect (last AKI grade mea-
sured within 10 days) and a long-term eﬀect (last AKI
grade measured within 11–90 days).
Material and Methods
The dog database of the Small Animal University Hospital of
Z€urich was retrospectively searched for billing of HES between
January 2013 and November 2015. Dogs were eligible to enter the
“exposed” cohort if they received ≥1 mL/kg HES 130/0.4d between
January 2013 and November 2015 and had a pretreatment serum
creatinine concentration measured as well as at least 1 additional
serum creatinine concentration determined between 2 and 20 days
post-HES administration.
The unexposed cohort consisted of all dogs hospitalized in the
ICU between January 2014 and November 2015 that received IV
isotonic crystalloid ﬂuids, and which had at least 2 serum crea-
tinine concentrations measured, which were at least 2 days apart
but determined within 20 days. Dogs that received any other syn-
thetic colloid were excluded.
Data retrieved from the medical records and compiled in a
spreadsheet were breed, sex, age, and weight for all patients. The
database and patient records were further searched for the number
of mL of HES administered per day, the total amount of HES
administered, the number of days of HES administration, the ﬁnal
diagnosis, blood product administration, other colloid administra-
tion, duration of hospital stay, date of discharge, and any avail-
able additional information regarding renal function including
urinalysis results, urine output, and ultrasonographic ﬁndings. The
cumulative amount of HES per kg body weight (mL/kg) adminis-
tered and the corresponding mL/kg/d were calculated for each
patient. The ﬁnal diagnosis found in the patient record was further
classiﬁed into 1 of the 21 groups of the International Statistical
Classiﬁcation of Diseases and Related Health Problems (ICD) sys-
tem.e If >1 diagnosis was available in 1 patient, the diagnosis most
likely associated with the primary presenting problem (e.g.,
abdominal for a dog presenting with vomiting caused by an
intestinal foreign body and concurrent mitral insuﬃciency and
hyperadrenocorticism) was used for the classiﬁcation. For statisti-
cal analysis, the ICD classiﬁcation was further narrowed into the
following groups: gastrointestinal (ICD XI, including parvovirosis
from ICD I), urogenital (ICD XIV), trauma (ICD XIX), and
others (all other ICD classiﬁcations including neoplasia, infectious
disease, respiratory, neurologic, and endocrinologic problems).
The database also was searched for blood analysis results,
and results for serum creatinine and albumin concentration were
recorded. Day 0 concentration for all blood variables was
deﬁned as the last result that was available before HES adminis-
tration. Serum creatinine concentration then was recorded each
available day until day 90 and serum albumin concentration
until day 7.
The AKI grade (AKI 1-AKI 5) was determined according to
the recently published IRIS guidelines for grading AKI (Table 1).
Patients without clinical or laboratory signs of AKI and a serum
creatinine concentration <140 lmol/L (1.6 mg/dL) and an increase
in serum creatinine concentration of <26.4 lmol/L (0.3 mg/dL)
within 48 hours were deﬁned as AKI 0. All available information
including serial serum creatinine concentrations before the start of
HES administration, urinalysis, and diagnostic imaging ﬁndings
was used for determination of AKI grade.
The last serum creatinine concentration and AKI grade, which
was determined during the time period of day 2–10 after the start
of HES or crystalloid administration, was used to deﬁne the short-
term AKI grade increase. The last serum creatinine concentration
and AKI grade determined during the time period of day 11–90
after the start of HES or crystalloid administration were used to
deﬁne the long-term AKI grade increase.
Statistical Analysis
Data were entered into a spreadsheet and double-checked by 2
of the authors. Descriptive statistical analysis was performed by
the statistical software program SPSS.f Normality was tested for
continuous data by the Shapiro-Wilk test. Normally distributed
data are presented as mean  standard deviation (SD), whereas
non-normally distributed data are presented as median and range
(minimum–maximum). Categorical data are described as frequen-
cies. Fisher’s exact test or chi-square test was used for association
of categorical variables, whereas a Mann-Whitney U-test was used
for continuous variables. The primary outcomes were development
Table 1. Modiﬁed acute kidney injury (AKI) grading as deﬁned by IRIS.
AKI
grade AKI description Serum creatinine level Creatinine change History, physical examination
0 No AKI <140 lmol/L (<1.6 mg/dL) < 26.4 lmol/L (<0.3 mg/dL) No clinical, laboratory or
diagnostic imaging signs of AKI
1 Nonazotemic AKI <140 lmol/L (<1.6 mg/dL) >26.4 lmol/L (>0.3 mg/dL)
increase within 48 hour
Any clinical, laboratory or diagnostic
imaging sign of AKI, oliguria, or
anuria >6 hour
2 Mild AKI 141–220 lmol/L (1.7–2.5 mg/dL) >26.4 lmol/L (>0.3 mg/dL)
within 48 hour
Documented AKI, static or
progressive azotemia, oliguria, or
anuria >6 hour
3 Moderate
to severe AKI
221–439 lmol/L (2.6–5.0 mg/dL) Documented AKI
4 440–880 lmol/L (5.1–10.0 mg/dL)
5 >880 lmol/L (>10 mg/dL)
AKI, acute kidney injury.
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of an AKI grade ≥1 (“new AKI short-term”) and an increase in
AKI grade (“AKI increase short-term”) within 10 days of HES
administration. A secondary outcome was an increase in AKI
grade within 11–90 days of HES administration (“AKI increase
long term”).
The primary exposure or risk factor was HES administration,
(a) as a categorical variable (yes/no), (b) cumulative amount of
HES per kg body weight (mL/kg), (c) mL/kg/d, or (d) number of
days HES was given. Other potential exposures or risks or con-
founding factors were whether natural colloids were given (yes/
no), whole blood transfusions administered (yes/no), the diagnosis
of the patient (ICD categories were collapsed into 4 categories),
age (continuous), sex (4 categories: intact or castrated males or
females, Table 2). The tested null hypotheses were that (1) HES
administration was not associated with development of a short-
term AKI grade ≥1, and HES administration was not associated
with a (2) short-term or (3) long-term increase of AKI grade in
dogs hospitalized in our intensive care unit, when adjusting for
potential confounding factors. The exposure variables were tested
for a univariable association with the short- and long-term out-
comes by a chi-squared or Fisher’s exact test, logistic regression
analysis, or both. Exposure variables with P ≤ .3 and potential
confounding variables were included in multivariable regression
models, which were built-in Stata 10g by a manual stepwise for-
wards and backwards procedure to test associations between expo-
sure and outcome variables. Exposure variables were included in
the model if they signiﬁcantly improved the model ﬁt assessed by
likelihood ratio test statistics with the signiﬁcance set at P ≤ .05
and Akaike information criteria. Multivariable logistic regression
(lrm) and ordinal logistic regression (olrm) models were used to
assess the eﬀect of HES on the AKI grade. In the lrm, the out-
come variable “AKI increase” was divided into 2 categories: Cate-
gory 0 included dogs that remained in the same AKI grade, and
category 1 included dogs that changed from 1 AKI grade into a
higher AKI grade. Four lrm were built assessing the eﬀect of the 4
primary exposure variables (HES applications a–d) on AKI
increase, adjusting for the eﬀect of other confounding variables.
In olrm, the outcome variable included 6 categories, namely the
AKI grades 0–5. Hence, in olrm, we tested the odds of changing
into a higher AKI grade in HES-exposed and HES-unexposed
dogs. Four olrm models were built, given the 4 primary exposure
variables (HES applications a–d), adjusting for the eﬀect of other
confounding variables. Statistical signiﬁcance was set at P < .05
for all analyses.
The ﬁnal models were evaluated for goodness of ﬁt by the Hos-
mer-Lemeshow test. Inﬂuential observations were detected using
Pearson residuals, hat matrix (leverage), and delta-betas.16
Results
A total of 184 dogs met the inclusion criteria. The
exposed cohort (HES) included 94 dogs with a mean
age of 7.3  3.5 years (range, 0.3–15.7 years) and a
median weight of 19.0 kg (range, 1–71 kg). Several
breeds were recorded with mixed breed dogs being most
frequent (n = 15, 14.1%), followed by Labrador Retrie-
ver (n = 6, 6.4%), Chihuahua and Jack Russell Terriers
(each n = 4, 4.3%), and Bernese mountain dogs (n = 3,
3.2%). Most dogs (88/94) received HES over >24 hours,
with a median time frame of 4 (range, 1–16) days. Dogs
in the HES group received a median amount of 69.4
(range, 2–429) mL per kg body weight HES, corre-
sponding to a median dose of 20.7 (range, 2–87) mL
per kg body weight per day. Hypoalbuminemia, deﬁned
as serum albumin concentration <20 g/L (2 g/dL), was
present in 48 of 88 (54.5%) dogs, and median serum
albumin concentration at presentation was 19.0 g/L
(range, 7–44 g/L; 1.9 g/dL, range, 0.7–4.4 g/dL). The
lowest serum albumin concentration within days 1–7
ranged from 8 to 30 g/L (0.8–3.0 g/dL; median, 20 g/L;
2.0 g/dL). Forty-three of 94 (45.7%) of the HES dogs
were presented for primary gastrointestinal problems,
Table 2. Frequencies in exposure variables in dogs exposed and unexposed to HES.
Variable (Exposure/Risk factor) Categories Unexposed n = 90 HES-exposed n = 94
Mean SD Mean SD P-value
Age (years) Continuous 8.5 4.0 7.3 3.5 .035
Median Range Median Range
HES mL/kg total Continuous 0 69.4 2–429
HES mL/kg/d Continuous 0 20.7 2–87
Number of HES days Continuous 0 4 1–16
n/N % n/N %
Diagnosis ICD 19: Trauma 14/90 15.6 14/94 14.9 .004
ICD 11: Gastrointestinal 20/90 22.2 43/94 45.7
ICD 14: Renal 11/90 12.2 11/94 11.7
Other ICD classes 45/90 50.0 26/94 27.7
Whole blood or pRBC transfusion Yes 4/90 4.4 22/94 23.4 <.001
No 86/90 95.6 72/94 76.6
Natural colloid transfusion Yes 2/90 2.2 35/94 37.2 <.001
No 88/90 97.8 59/90 62.8
Other synthetic colloids Yes 0/90 100 4/94 4.3 .066
No 90/90 0 90/94 95.7
Sex Female intact 10/90 11.1 14/94 14.9 .129
Female castrated 41/90 45.6 32/94 34.0
Male intact 13/90 14.4 25/94 26.6
Male castrated 26/90 28.9 23/94 24.5
HES application Yes 0/94 0 90/90 100
No 94/94 100 0/90 0
ICD, International Statistical Classiﬁcation of Diseases and Related Health Problems; pRBC, packed red blood cells.
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followed by 27.7% for other diseases, 14.9% for
trauma, and 11.7% for urogenital diseases (Table 2).
All dogs within the HES group received crystalloid
solutions in addition to HES.
In addition to HES solutions, 22 of 94 dogs (23.4%)
received red blood cells in the form of packed red blood
cells (pRBC) or fresh whole blood, 35 of 94 (37.2%)
dogs received natural colloids (whole blood, plasma,
human albumin), and 4 dogs (4.3%) received a bolus of
10% HES-200/0.5 at the time of presentation (Table 2).
The unexposed cohort consisted of 90 dogs with a
mean age of 8.6  4.0 years (range, 0.3–17.6 years) and
a median weight of 17.2 kg (range, 1.6–53.9 kg). Several
breeds were represented with mixed breed dogs being
most frequent (n = 15, 16.7%), followed by Pugs
(n = 5, 5.6%), Chihuahua and Golden Retriever (each
n = 4, 4.4%), and Labrador Retriever (n = 3, 3.3%).
Most dogs presented with various diseases (45/90, 50%)
followed by gastrointestinal causes (20 of 90, 22.2%),
trauma (14/90, 15.6%), and renal causes (11/90,
12.2%). Only 4 of 90 (4.4%) and 2 of 90 (2.2%) dogs
required red blood cell transfusions or natural colloids,
respectively. None of the unexposed dogs received any
other synthetic colloids. Five of 74 dogs in the unex-
posed group presented with a serum albumin concentra-
tion <20 g/L (2 g/dL), and the median serum albumin
concentration was 29.0 g/L (2.9 g/dL) with a range of
15–46 g/L (1.5–4.6 g/dL), whereas the lowest serum
albumin concentration within the ﬁrst 7 days ranged
from 13 to 49 g/L (1.3–4.9 g/dL; median, 26.0 g/L;
2.6 g/dL).
Exposed and unexposed cohorts were comparable in
terms of sex (P = .129) and weight (P = .839), but not
age (P = .035). Groups also were signiﬁcantly diﬀerent
in terms of diagnosis (Table 2) and requirement for
blood products and natural colloids, with the HES
cohort requiring more blood products and natural col-
loids (Table 2). Dogs receiving HES stayed signiﬁcantly
longer (P = .041) in the hospital (median, 8 days; range,
3–43 vs 7 days; range, 2–82 days), and signiﬁcantly
fewer HES-treated dogs left the hospital (77.7% vs
90.0%, P = .028).
Serum creatinine concentrations were not signiﬁcantly
diﬀerent at most time points (Table 3). Results from
days 8 to 20 are not reported because <10 measure-
ments per group were available.
The AKI grade was not statistically diﬀerent between
exposed and unexposed cohorts at various time points
(Table 4) in the univariable analysis. From exposed and
unexposed dogs that presented with no signs of AKI
(AKI grade 0) at the beginning of the study, 3 in each
cohort developed AKI within 10 days (P = 1.000). Of
the 3 dogs receiving HES and developing AKI (AKI
grade ≥1), 2 dogs received HES over 14 days and 1 dog
over 3 days.
Long-term follow-up of the AKI grade increase was
possible in 35 HES-exposed (37.2%) and 38 unexposed
(42.2%) dogs. None of these dogs showed an increase
in AKI grade from presentation to day 11–90. Of the 6
dogs receiving HES that showed an increase in AKI
grade during the short-term period, none were available
for long-term evaluation because all were euthanized
(after 4–17 days of hospitalization, euthanasia was not
related to renal disease).
In the subgroup of dogs presented with preexisting
AKI (AKI grade 1–5 at day 0), no statistically signiﬁ-
cant increase in AKI grade was found between dogs
exposed and unexposed to HES (P = .298). None of the
dogs available for the long-term time period showed an
increase in AKI grade (Table 4).
Table 3. Comparison of creatinine concentrations (crea) at various time points in dogs exposed (HES) and unex-
posed to HES.
Variable
Unexposed n = 90 HES exposed n = 94
P-valuen Median min max n Median min max
Crea day 0 (lmol/L) 90 85.5 18 1144 94 71.5 17 1240 .077
Crea day 0 (mg/dL) 0.97 0.20 12.94 0.81 0.19 14.03
Crea day 2 (lmol/L) 35 71.0 39 1056 40 56 26 455 .071
(mg/dL) 0.80 0.44 11.95 0.63 0.29 5.15
Crea day 3 (lmol/L) 26 76.0 18 1014 35 73.0 20 511 .610
(mg/dL) 0.86 0.20 11.47 0.83 0.23 5.78
Crea day 4 (lmol/L) 20 81.5 43 739 28 69.0 18 701 .067
(mg/dL) 0.92 0.49 8.36 0.78 0.20 7.93
Crea day 5 (lmol/L) 12 79.0 37 633 25 68.0 18 564 .142
(mg/dL) 0.89 0.42 7.16 0.77 0.20 6.38
Crea day 6 (lmol/L) 15 68.0 21 257 13 73.0 20 179 .717
(mg/dL) 0.77 0.24 2.91 0.83 0.23 2.02
Crea day 7 (lmol/L) 15 85.0 40 556 9 64.0 18 201 .238
(mg/dL) 0.96 0.45 6.29 0.72 0.20 2.27
Last crea within days 2–10 (lmol/L) 84 78.5 18 1014 39 66.5 19 701 .060
(mg/dL) 0.89 0.20 11.47 0.75 0.21 7.93
Last crea within days 11–90 (lmol/L) 40 76.5 20 356 39 65.0 18 1768 .136
(mg/dL) 0.87 0.23 4.03 0.74 0.20 20.00
Crea: serum creatinine concentration.
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Results of the ordinal logistic regression model identi-
ﬁed “number of applied HES days” as signiﬁcantly
associated with the short-term increase in AKI grade
(P = .038). One additional day of HES administration
was associated with an 18% increase in odds of having
a higher AKI grade than before. Thus, for every day,
HES was given, the odds of the patient being classiﬁed
in the high category of AKI vs the low and middle cate-
gories of AKI were 1.18 times greater (Table 5). How-
ever, the association between short-term increase in
AKI grade and the application of HES (yes/no), HES
mL/kg, and HES mL/kg/d was not signiﬁcant
(P = .341, P = .224 and P = .529, respectively).
The multivariable logistic regression model also iden-
tiﬁed the number of days of HES administration as sig-
niﬁcantly associated with a short-term change from
AKI grade 0 to an AKI grade ≥1 (P = .042), whereas
exposure to HES (yes/no), HES mL/kg/d, and HES
mL/kg was not signiﬁcantly associated (P = .329,
P = .225 and P = .504, respectively). With every addi-
tional day of HES application, the odds of developing
AKI was 1.17 times higher (Table 5).
When building the lrm and olrm, in a manual step-
wise forwards and backwards procedure, the simple
models including solely the risk factor “number of days
of HES administration” and none of the other risk fac-
tors listed in Table 2 had the best model ﬁt.
Looking at the long-term eﬀect of HES, none of the
dogs showed a persistent increase in AKI grade; there-
fore, it was not possible to perform a multivariable
analysis.
Discussion
Studies in humans indicate an increased need for
renal replacement therapy7–9 and increased mortality9 in
septic and critically ill patients after HES administra-
tion. The PRAC therefore restricted HES use in human
patients to treatment of acute blood-loss hypovolemia
and prohibited its use in critically ill patients or patients
with sepsis or burn injury.b
In contrast to these studies in humans, we did not
ﬁnd an association between HES administration or
HES dose and an increase in AKI grade in dogs receiv-
ing HES 130/0.4 in an ICU setting. This ﬁnding is in
agreement with another veterinary study evaluating the
eﬀect of HES 130/0.4 administration on serum crea-
tinine concentrations in ICU patients.15 The HES popu-
lation in our study included mainly patients with
gastrointestinal or abdominal causes of disease, and
although septic patients were not speciﬁcally identiﬁed,
the incidence of severe sepsis patients is expected to be
very low. We did not compare dogs with and without
signs of sepsis because our study was designed to evalu-
ate a critically ill population of dogs rather than a sub-
group of septic dogs. Other recent studies in humans
investigating adverse renal eﬀects of HES administra-
tion in surgical and trauma patients, but also critically
ill patients, did not show an increased risk of AKI after
HES administration17–19, indicating that conclusive
studies also are needed in human medicine.
A dose-response relationship of HES administration
has been proposed, and the PRAC recommends using
HES solutions at the lowest eﬀective dose for the short-
est period of time possible, generally for a maximum of
24 hours and avoiding administration as a constant rate
infusion (CRI). In contrast to a study that investigated
a pentastarch solution and found that higher HES-250/
0.5 doses (mL/kg/h) were associated with an increased
risk of death and AKI, and a higher HES dosage per
kilogram body weight and per kilogram body weight
per day were not associated with increased risk of AKI
Table 4. Comparison of AKI grade before HES/crys-
talloid administration and after HES/crystalloid admin-
istration (AKI grade increase/newly developed AKI) in
dogs of the exposed and unexposed cohort.
Variable
Unexposed
n = 90 HES n = 94
P-valuen/N % n/N %
AKI grade of dogs at day 0 (before HES administration)
AKI grade 0 (no AKI) 61/90 67.8 70/94 74.5 .333
AKI grade 1–5 (AKI) 29/90 32.2 24/94 25.5
AKI grade 1 4/90 4.4 4/94 4.3 .628
AKI grade 2 10/90 11.1 8/94 8.5
AKI grade 3 9/90 10.0 7/94 7.4
AKI grade 4 2/90 2.2 4/94 4.3
AKI grade 5 4/90 4.4 1/94 1.1
AKI grade increase in dogs after HES/Crystalloid administration
(all dogs)
AKI grade increase
(short-terma)
3/84 3.6 6/86 7.0 .496
AKI grade increase
(long termb)
0/38 0.0 0/35 0.0 NA
AKI grade increase in dogs after HES/Crystalloid administration
(only dogs presenting with AKI grade 0 at time point 0)
Newly developed AKI
(short terma)
3/57 5.3 3/66 4.5 1.000
AKI grade increase in dogs after HES/Crystalloid administration
(only dogs with preexisting AKI, AKI grade 1–5 at time point 0)
AKI grade increase
(short-terma)
1/27 3.7 3/20 15 .298
AKI grade increase
(long termb)
0/13 0 0/8 0 NA
aShort-term, AKI grade increase within 10 days.
bLong term, AKI grade increase within 11–90 days; NA, not
assessed.
Table 5. Multivariable analysis: signiﬁcant eﬀect on
short-terma AKI grade in dogs exposed (n = 90) or
unexposed (n = 94) to HES (January 2013–November
2015).
Variable (Exposure/
Risk factor) Odds Ratio
95% Conﬁdence
Intervals P value
HES days appliedb 1.17 (1.01–1.37) .042
HES days appliedc 1.18 (1.01–1.37) .038
aShort-term, AKI grade increase within 2–10 days.
bLogistic regression model.
cOrdinal logistic regression model. None of the other included
risk factors improved the model ﬁt.
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in this patient population. Whereas exposure to HES
itself as well as cumulative HES dose (mL/kg and mL/
kg/d) was not associated with an increase in AKI grade,
the number of days of HES administration was signiﬁ-
cantly associated with risk of increased AKI grade
within 10 days of HES exposure (short-term eﬀect).
Hence, although the use of HES itself does not seem to
cause AKI, the duration of HES treatment should be
kept as short as possible. To our knowledge, ours is the
ﬁrst veterinary study investigating the time period of
HES administration on changes in AKI grade. The med-
ian number of days of HES administration in our study
was 4 (range, 1–16 days), and HES was administered as
a CRI in the majority of cases because HES solutions
are used for colloid osmotic support in patients with sev-
ere hypoalbuminemia (<16–20 g/L) at our institution.
Of the 3 dogs that developed “new AKI”, 2 received
long-term HES administration (14 days). However,
despite long-term use, the patient with the longest dura-
tion of HES administration (16 days, total cumulative
dose of 429 mL/kg) did not develop AKI.
The mechanism of action of renal impairment by
HES is not fully understood. Although newer HES
solutions such as HES 130/0.4 have a short half-life and
no plasma accumulation occurs over time20, HES accu-
mulates in the lysosomes of a wide range of tissues and
highest concentrations have been identiﬁed in the proxi-
mal renal tubular cells.21 In the kidney, cellular uptake
of HES leads to osmotic nephrosis, characterized by
accumulation of intracellular water, cytoplasmic swel-
ling and cellular disruption.21 The renal impairment
seems to occur independent of inﬂammation as shown
in a rat model of septic AKI, but changes are increased
with concurrent sepsis.22
In an in vitro model of human proximal tubular cells,
various HES solutions (3–200 kDa) induced decreased
cell viability.23 It was concluded that not the type or size
of the HES molecule but solely the number of molecules
or cumulative dose was responsible for proximal tubular
cell injury.23 Hydroxyethyl starch has been shown to
persist in the renal parenchymal cells of dogs up to
18 days.21,24 This cumulative dose eﬀect is supported by
other studies in human patients, and dosages as low as
39 mL/kg HES-130/0.4 may lead to AKI.25 In contrast
to these studies, our results suggest that the time frame
of administration had a more pronounced eﬀect than
the total cumulative dose. However, the above-men-
tioned study in rats detected renal tubular cell injury
with doses of 50 mL/kg HES administered over 6 hours,
whereas our dogs received a median dose of 69.4 mL/kg
over a median of 4 days, corresponding to a much lower
median daily dose of 20.7 mL/kg. A study that investi-
gated larger median cumulative dosages of 87 mL/kg
also failed to show an increase in serum creatinine con-
centration compared to dogs receiving only crystalloid
ﬂuid therapy.15 No attempt at identiﬁcation of risk fac-
tors was made in this study.
Whereas histopathological changes are seen within
24 hours after exposure22, increases in serum creatinine
concentrations may lag behind the development of
AKI.26 In another study, serum creatinine concentration
peaked at day 38, yet another study showed an increase
in serum creatinine concentration within 24 hours of
HES application to septic rats.22 In our study, peak
serum creatinine concentration could not be determined
because of a low number of dogs evaluated at each day
and presence of measurement bias (dogs with higher
serum creatinine concentrations on 1 day were more
likely to have additional measurements than dogs with
normal results over several days). Because changes in
serum creatinine concentrations may lag behind renal
injury, only dogs with serum creatinine concentrations
and AKI grades determined at least 48 hours after the
start of HES administration were included.
In humans, long-term eﬀects caused by tissue accu-
mulation are expected 20 days after initial exposure;
therefore, continued monitoring is important and long-
term evaluation of renal function may be as important
as short-term monitoring.9 The PRAC recommends
monitoring of renal function (serum creatinine concen-
tration) up to 90 days after HES exposure.b Whereas
the number of dogs available for long-term evaluation
in our study was small, comparison of serum crea-
tinine concentration and increases in AKI grade at
various time points up to 90 days after HES in dogs
exposed and unexposed to HES were not diﬀerent.
None of the dogs that were available for long-term
evaluation had an increased AKI grade, but the 6
dogs that showed an increase in AKI grade during the
short-term period were not available for long-term
evaluation. It therefore remains speculative if those
patients may have progressed to more severe AKI or
if renal regeneration potentially could have led to a
reversal of AKI.
Other studies investigating adverse renal eﬀects of
HES solutions in dogs are rare. In a canine hemor-
rhagic shock model and goal-directed ﬂuid therapy by
HES-130/0.4, high dosages did impair renal function
(deﬁned as a decrease in creatinine clearance).27 Dogs in
this study received 0.4–0.45 mL/kg/min of HES
resulting in a very high mean cumulative dose of 110–
122 mL/kg that is not commonly used in clinical
situations. Hence, the clinical relevance is questionable.
A recently published retrospective study evaluating the
eﬀects of HES-250/0.5 on survival and development of
AKI in dogs found decreased survival and increased
risk of AKI in dogs receiving HES-250/0.5.14 Acute kid-
ney injury was deﬁned as a doubling of serum crea-
tinine concentration during the hospital stay. The
results therefore are not comparable to our study
results, because we used a diﬀerent AKI case deﬁnition
and another type of HES. The only other study of dogs
evaluating HES eﬀects on renal function investigated
the same tetrastarch solution (HES-130/0.4) as did our
study and did not show any impairment of renal
function, as determined by absolute serum creatinine
concentrations and changes in serum creatinine concen-
trations within 2 and 12 weeks, respectively.15 Their
results support our study ﬁndings. Although these
results suggest that the type of HES may inﬂuence the
incidence of adverse renal eﬀects, another study con-
cluded that not the type or size of the HES molecule
HES-130/04 and AKI Grade in Dogs 439
but solely the number of molecules or cumulative dose
was responsible for proximal tubular cell injury.23
Hydroxyethyl starch solutions can be divided into
hetastarches, pentastarches, and tetrastarches depending
on their grade of substitution with hydroxyethyl at the
C2 and C6 site. The newest generation of HES solution
is a tetrastarch (substitution grade, 0.4–0.42) with a
lower molecular weight of 130 kd and a low substitu-
tion ratio (0.9). The lower molecular weight, lower sub-
stitution grade, and high C2:C6 substitution ratio
theoretically should decrease adverse eﬀects on coagula-
tion and renal damage. Although reports in human
medicine are inconsistent in terms of HES type, and
additional factors such as the presence of sepsis aﬀect
pathophysiological changes22, present veterinary studies
may suggest that HES-130/0.4 is less likely than pen-
tastarch to induce AKI or increase AKI grade in dogs
if used at moderate dosages.
To our knowledge, our study is also the ﬁrst investi-
gating the impact of HES on patients with preexisting
renal disease. The administration of HES 130/0.4 in
dogs with preexisting renal disease, deﬁned as AKI
grade 1–5 at day 0, did not signiﬁcantly worsen AKI
grade or increase serum creatinine concentrations when
compared to dogs with similar AKI grades receiving
only isotonic crystalloid solutions. Additionally, none
of the dogs available for the evaluation of a long-term
eﬀect of HES on AKI showed an increase in AKI
grade. This ﬁnding is in accordance with the human lit-
erature where the 6S study also did not ﬁnd an
increased risk of worsening renal function in a group of
patients with preexisting renal disease.9 However, more
dogs in the HES group (15% vs 3.7%, P = .298)
showed a short-term increase in AKI grade, and
although this ﬁnding may be a consequence of the
potentially sicker group of dogs requiring HES, this
ﬁnding needs further evaluation before ﬁrm conclusions
can be drawn.
Dogs receiving HES stayed signiﬁcantly longer in the
hospital and survival to discharge was signiﬁcantly
lower. Whether lower survival was related to HES
administration or simply associated with a more severe
underlying disease cannot be determined. As in another
study14, the dogs in our HES group seemed to be
sicker, presenting with lower admission serum albumin
concentrations, prolonged hospital stay and an
increased need for blood products. Illness severity
scores were not determined because of incomplete infor-
mation. However, because potentially sicker dogs were
not more prone to development of AKI after HES
administration, we conclude that administration of HES
did not inﬂuence the development of AKI and survival
was independent of HES administration.
As does any retrospective study, our study has several
limitations. First, the 2 groups diﬀered in terms of age,
diagnosis, blood product requirements, and serum albu-
min concentration. Age, blood product requirements,
and ICD score were not statistically signiﬁcant risk fac-
tors in the multivariable models and did not improve
model ﬁt. Therefore, we assume that our study results
were not strongly biased by diﬀerences in age or
diagnosis in the exposed and unexposed groups. Fur-
thermore, if age or the ICD score had an inﬂuence on
the outcome, it would have been adjusted for in the
multivariable models. However, a prospective random-
ized clinical control trial would strengthen the causal
relationship between HES exposure and AKI grade.
Low serum albumin concentration was the reason for
HES administration in many of the dogs and was asso-
ciated with abdominal diseases, making it diﬃcult to
ﬁnd a matching control group. Second, data were col-
lected retrospectively, and serum creatinine concentra-
tions and AKI grades were not available at
predetermined time points in all dogs. A bias is
expected because dogs with an increase in serum crea-
tinine concentration were probably more prone to have
follow-up serum creatinine concentrations measured.
However, the median serum creatinine concentrations
of both cohorts remained within the reference interval
throughout most time points of the study, indicating
that enough dogs with serum creatinine concentrations
within the reference interval were included.
Third, the diﬀerent AKI deﬁnitions used in the pub-
lished veterinary studies hinder direct comparisons. We
elected to use the IRIS guidelines for AKI grading
because these are the most recently published veterinary
guidelines, are based on laboratory and diagnostic
imaging ﬁndings other than merely serum creatinine
concentrations and allowed us to account for diﬀerent
grades of AKI. However, because baseline serum crea-
tinine concentrations generally were not available (dogs
presented already sick) and not all dogs underwent lab-
oratory and diagnostic imaging evaluation, the “true”
AKI grade could have been falsely high (if presented
with prerenal azotemia) or falsely low (when an increase
in serum creatinine concentration within 48 hours was
missed).
Fourth, no attempt was made to evaluate dogs with
short-term (<24 hours) administration of HES because
only a few dogs were treated for <24 hours. Fifth, con-
current crystalloid ﬂuid administration has not been
investigated as a potential risk factor and an eﬀect on
study results cannot be completely ruled out even
though all dogs receiving HES also received crystalloid
ﬂuids.
In conclusion, HES administration to critically ill
dogs was not associated with an increase in AKI grade
within 10 days and the cumulative HES dose was not a
risk factor for the development of AKI. However, the
number of HES days signiﬁcantly increased the odds of
an increase in AKI grade (P = .04). Although dogs pre-
sented without AKI had the same risk to newly acquire
AKI (P = 1.0), more dogs with preexisting AKI showed
an increase in AKI after treatment with HES, but this
ﬁnding was not statistically signiﬁcant.
Based on our data, HES can be safely administered
to critically ill dogs, but the time period of administra-
tion should be kept as short as possible. The eﬀect of
HES administration on long-term renal function and
in dogs with preexisting renal disease must be further
evaluated before additional recommendations can be
made.
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Footnotes
a Garcia AM, Rudloﬀ E, and Kirby R. Eﬃcacy and adverse
eﬀects of hetastarch/crystalloid combination in 21 hypotensive
cats. J Vet Emerg Crit Care 2002; 12(3):200
b European Medicine Agency. Press release: European Medicine
Agency, (EMA) PRAC conﬁrms that hydroxyethyl starch solu-
tions (HES) should no longer be used in patients with sepsis or
burn injuries or in critically ill patients. Available at http://www.
ema.europa.eu/docs/en_GB/document_library/Referrals_document/
Solutions_for_infusion_containing_hydroxyethyl_starch/Position_
provided_by_CMDh/WC500153119.pdf. Accessed February 20,
2014
c http://www.iris-kidney.com/pdf/grading-of-acute-kidney-injury.
pdf
d hydroxyethyl starch 130/0.4; Voluven, Voluven balanced, Fre-
senius Kabi, Switzerland
e http://apps.who.int/classifications/icd10/browse/2016/en
f IBM SPSS v.21 for Mac OS X; IBM Corporation, New York, NY
g StataCorp, Data Analysis and Statistical Software, College Sta-
tion, Texas
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